Ellagic Acid and liver

What 2 graded rows on ellagic acid agree on for liver, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Ellagic Acid page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Ellagic Acid page, with its PubMed record.

Supplement

Ellagic Acid Choose another

2 rows · 104 people

They agree: both rows found an improvement.

No difference

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside.

From the rows

The best-graded row, grade D, is a randomized trial of 60 people (2025) and found an improvement.

The rows run from 44 to 60 people, published in 2025: 2 single studies.

2 improved

Grade DLiver fat (hepatorenal index) and liver enzymes in fatty liver disease · Improved
RCT · n 60 · 2025 · Adults with metabolic dysfunction-associated steatotic liver disease (MASLD) on a reduced-calorie diet (Iran)
200 mg/day · 8 weeks
Versus placebo, liver fat index (MD −0.23), liver stiffness (−0.47 kPa), ALT (−27.9 U/L), AST, fasting glucose, triglycerides, LDL and hs-CRP fell and HDL rose (all P<0.05).
Row on the Ellagic Acid page · PubMed 40877731 (opens PubMed)
Grade DInsulin resistance and liver enzymes in fatty liver disease · Improved
RCT · n 44 · 2025 · Adults with non-alcoholic fatty liver disease (Iran)
180 mg/day · 8 weeks
Insulin, insulin resistance, triglycerides, LDL, AST, ALT, ALP, GGT, malondialdehyde and CRP fell and antioxidant capacity rose in the ellagic acid group; fasting glucose, total cholesterol and HDL did not change in either group.
Row on the Ellagic Acid page · PubMed 39885430 (opens PubMed)